NAFLD patients exhibit elevated L-FABP expression levels, which gradually decline as the condition progresses, thereby diminishing the liver cells’ capacity to resist lipotoxicity. This evidence concerns the gene FABP1 and metabolic dysfunction-associated steatotic liver disease.